These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7284995)

  • 1. Use of human prostate-specific antigen in monitoring prostate cancer.
    Kuriyama M; Wang MC; Lee CI; Papsidero LD; Killian CS; Inaji H; Slack NH; Nishiura T; Murphy GP; Chu TM
    Cancer Res; 1981 Oct; 41(10):3874-6. PubMed ID: 7284995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer.
    Killian CS; Yang N; Emrich LJ; Vargas FP; Kuriyama M; Wang MC; Slack NH; Papsidero LD; Murphy GP; Chu TM
    Cancer Res; 1985 Feb; 45(2):886-91. PubMed ID: 2578313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay.
    Kuriyama M; Wang MC; Papsidero LD; Killian CS; Shimano T; Valenzuela L; Nishiura T; Murphy GP; Chu TM
    Cancer Res; 1980 Dec; 40(12):4658-62. PubMed ID: 6159971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical evaluation of prostate antigen (PA) in prostate cancer].
    Kuriyama M
    Gan No Rinsho; 1985 May; 31(6 Suppl):606-10. PubMed ID: 2411962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients].
    Okubo Y; Ito T
    Hinyokika Kiyo; 1999 Jan; 45(1):25-30. PubMed ID: 10086262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
    Leibovitch I; Pinthus Y; Sella BA; Ramon J
    Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
    Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
    Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
    Yashi M; Muraishi O; Kobayashi Y; Tokue A; Nanjo H
    Prostate; 2002 May; 51(2):84-97. PubMed ID: 11948963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of real-time reverse transcription-PCR for prostate-specific antigen mRNA to discriminate between blood samples from healthy volunteers and from patients with metastatic prostate cancer.
    Patel K; Whelan PJ; Prescott S; Brownhill SC; Johnston CF; Selby PJ; Burchill SA
    Clin Cancer Res; 2004 Nov; 10(22):7511-9. PubMed ID: 15569981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
    Tarle M
    Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
    Zhigang Z; Wenlu S
    Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers.
    Langer F; Chun FK; Amirkhosravi A; Friedrich M; Leuenroth S; Eifrig B; Bokemeyer C; Francis JL
    Thromb Haemost; 2007 Mar; 97(3):464-70. PubMed ID: 17334515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
    Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer.
    Tahir SA; Ren C; Timme TL; Gdor Y; Hoogeveen R; Morrisett JD; Frolov A; Ayala G; Wheeler TM; Thompson TC
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3653-9. PubMed ID: 14506154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
    Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
    Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of the serum concentration of prostate-specific antigen as a biological marker in the evolution of disseminated prostatic cancer].
    Morote Robles J; de Torres Mateos JA; Soler-Roselló A
    Actas Urol Esp; 1988; 12(2):152-7. PubMed ID: 2458015
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.
    Birtle AJ; Freeman A; Masters JR; Payne HA; Harland SJ;
    Cancer; 2003 Dec; 98(11):2362-7. PubMed ID: 14635070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality.
    Mirtti T; Laine VJ; Hiekkanen H; Hurme S; Rowe O; Nevalainen TJ; Kallajoki M; Alanen K
    APMIS; 2009 Mar; 117(3):151-61. PubMed ID: 19245588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients.
    Grande M; Carlström K; Rozell BL; Stege R; Pousette A
    Clin Cancer Res; 2000 May; 6(5):1790-5. PubMed ID: 10815899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.